Efficiency of late conversion from mycophenolate mofetil to everolimus in kidney graft recipients with posttransplant malignancy
Malignancy is one of the leading causes of death in recipients with a kidney grafts. The use of proliferative signal inhibitors (PSI) is one of the approaches to solve this problem.Aim: to evaluate the effi cacy and safety of everolimus in combination with reduced dose of calcineurin inhibitors (CNI)...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Federal Research Center of Transplantology and Artificial Organs named after V.I.Shumakov
2018-01-01
|
| Series: | Вестник трансплантологии и искусственных органов |
| Subjects: | |
| Online Access: | https://journal.transpl.ru/vtio/article/view/823 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849774565004148736 |
|---|---|
| author | I. G. Kim N. A. Tomilina N. D. Fedorova I. V. Ostrovskaya I. A. Skryabina |
| author_facet | I. G. Kim N. A. Tomilina N. D. Fedorova I. V. Ostrovskaya I. A. Skryabina |
| author_sort | I. G. Kim |
| collection | DOAJ |
| description | Malignancy is one of the leading causes of death in recipients with a kidney grafts. The use of proliferative signal inhibitors (PSI) is one of the approaches to solve this problem.Aim: to evaluate the effi cacy and safety of everolimus in combination with reduced dose of calcineurin inhibitors (CNI) in patients with posttransplant malignancy.Materials and methods. 62 kidney graft recipients (KGR) with neoplasia were converted from mycophenolate mofetil to everolimus in combination with reduced dose of CNI at 83.5 ± 69.3 months after transplantation. The duration follow-up was 35.5 ± 26.9 month. The effectiveness of management was assessed by patient survival, type of immunosuppression therapy, renal function and proteinuria. The patient survival in PSI group was compared with the survival in the patients in control group (n = 145), who did not receive everolimus.Results. 10-year and 15-year patient survival was 92% and 85,7% in patients treated with PSi versus 61.1% and 52.8% in control group (p < 0.0003). Patients survival with everolimus-therapy after 1 year was 86.5%, after 3 year it was 64.2%, and by the end of 5 years the possibility of treatment with everolimus decreased to 50.8%, mainly due to the proteinuria and other adverse events. The recurrence rate of tumors among patients, who was treated with everolimus for 35 (26; 60) months was 13.2%. Creatinine level in serum increased from 0.13 ± 0.04 to 0.15 ± 0.09 mmol during the treatment (p < 0.031), and the daily proteinuria increased from 0.18 ± 0.25 g/day to 0.75 ± 1.63 g/day, p < 0.011.Conclusion. The usage of PSi improves long-term survival of KTR with posttransplant malignancy and demonstrates a relatively low tumors recurrence rate (13.2%) over a period of 35 months. However this treatment is not suitable for many patients and it was stopped in almost half of them due to increasing proteinuria or serious adverse events. |
| format | Article |
| id | doaj-art-e4db57360d3a455391b4255b962f26d0 |
| institution | DOAJ |
| issn | 1995-1191 |
| language | Russian |
| publishDate | 2018-01-01 |
| publisher | Federal Research Center of Transplantology and Artificial Organs named after V.I.Shumakov |
| record_format | Article |
| series | Вестник трансплантологии и искусственных органов |
| spelling | doaj-art-e4db57360d3a455391b4255b962f26d02025-08-20T03:01:39ZrusFederal Research Center of Transplantology and Artificial Organs named after V.I.ShumakovВестник трансплантологии и искусственных органов1995-11912018-01-01194162610.15825/1995-1191-2017-4-16-26656Efficiency of late conversion from mycophenolate mofetil to everolimus in kidney graft recipients with posttransplant malignancyI. G. Kim0N. A. Tomilina1N. D. Fedorova2I. V. Ostrovskaya3I. A. Skryabina4V.I. Shumakov National Medical Research Center of Transplantology and Artifi cial Organs of the Ministry of Healthcare of the Russian Federation; G.N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology.V.I. Shumakov National Medical Research Center of Transplantology and Artifi cial Organs of the Ministry of Healthcare of the Russian Federation; A.I. Evdokimov Moscow State Medical Stomatological University.City Hospital № 52.City Hospital № 52.City Hospital № 52.Malignancy is one of the leading causes of death in recipients with a kidney grafts. The use of proliferative signal inhibitors (PSI) is one of the approaches to solve this problem.Aim: to evaluate the effi cacy and safety of everolimus in combination with reduced dose of calcineurin inhibitors (CNI) in patients with posttransplant malignancy.Materials and methods. 62 kidney graft recipients (KGR) with neoplasia were converted from mycophenolate mofetil to everolimus in combination with reduced dose of CNI at 83.5 ± 69.3 months after transplantation. The duration follow-up was 35.5 ± 26.9 month. The effectiveness of management was assessed by patient survival, type of immunosuppression therapy, renal function and proteinuria. The patient survival in PSI group was compared with the survival in the patients in control group (n = 145), who did not receive everolimus.Results. 10-year and 15-year patient survival was 92% and 85,7% in patients treated with PSi versus 61.1% and 52.8% in control group (p < 0.0003). Patients survival with everolimus-therapy after 1 year was 86.5%, after 3 year it was 64.2%, and by the end of 5 years the possibility of treatment with everolimus decreased to 50.8%, mainly due to the proteinuria and other adverse events. The recurrence rate of tumors among patients, who was treated with everolimus for 35 (26; 60) months was 13.2%. Creatinine level in serum increased from 0.13 ± 0.04 to 0.15 ± 0.09 mmol during the treatment (p < 0.031), and the daily proteinuria increased from 0.18 ± 0.25 g/day to 0.75 ± 1.63 g/day, p < 0.011.Conclusion. The usage of PSi improves long-term survival of KTR with posttransplant malignancy and demonstrates a relatively low tumors recurrence rate (13.2%) over a period of 35 months. However this treatment is not suitable for many patients and it was stopped in almost half of them due to increasing proteinuria or serious adverse events.https://journal.transpl.ru/vtio/article/view/823kidney transplantationimmunosuppressioneverolimus |
| spellingShingle | I. G. Kim N. A. Tomilina N. D. Fedorova I. V. Ostrovskaya I. A. Skryabina Efficiency of late conversion from mycophenolate mofetil to everolimus in kidney graft recipients with posttransplant malignancy Вестник трансплантологии и искусственных органов kidney transplantation immunosuppression everolimus |
| title | Efficiency of late conversion from mycophenolate mofetil to everolimus in kidney graft recipients with posttransplant malignancy |
| title_full | Efficiency of late conversion from mycophenolate mofetil to everolimus in kidney graft recipients with posttransplant malignancy |
| title_fullStr | Efficiency of late conversion from mycophenolate mofetil to everolimus in kidney graft recipients with posttransplant malignancy |
| title_full_unstemmed | Efficiency of late conversion from mycophenolate mofetil to everolimus in kidney graft recipients with posttransplant malignancy |
| title_short | Efficiency of late conversion from mycophenolate mofetil to everolimus in kidney graft recipients with posttransplant malignancy |
| title_sort | efficiency of late conversion from mycophenolate mofetil to everolimus in kidney graft recipients with posttransplant malignancy |
| topic | kidney transplantation immunosuppression everolimus |
| url | https://journal.transpl.ru/vtio/article/view/823 |
| work_keys_str_mv | AT igkim efficiencyoflateconversionfrommycophenolatemofetiltoeverolimusinkidneygraftrecipientswithposttransplantmalignancy AT natomilina efficiencyoflateconversionfrommycophenolatemofetiltoeverolimusinkidneygraftrecipientswithposttransplantmalignancy AT ndfedorova efficiencyoflateconversionfrommycophenolatemofetiltoeverolimusinkidneygraftrecipientswithposttransplantmalignancy AT ivostrovskaya efficiencyoflateconversionfrommycophenolatemofetiltoeverolimusinkidneygraftrecipientswithposttransplantmalignancy AT iaskryabina efficiencyoflateconversionfrommycophenolatemofetiltoeverolimusinkidneygraftrecipientswithposttransplantmalignancy |